Comments
Shares of Strides Arcolab rose 4 per cent today as it entered into a pact with Sun Pharma to buy from it erstwhile Ranbaxy’s two divisions in central nervous system (CNS) segment in India for Rs 165 crore.
The stock gained 3.98 per cent to Rs 1,191.50 on the BSE.
On the NSE, shares of Strides went up by 3.49 per cent to Rs 1,191.90.
Sun Pharma’s scrip gained 0.75 per cent to Rs 911.90 but later pared the gains and was trading at Rs 899.50, down 0.62 per cent on the BSE.
Sun Pharma and Strides have entered into a definitive agreement related to erstwhile Ranbaxy’s ‘Solus’ and ‘Solus Care’ divisions operating in the CNS segment in India, Strides had said in a statement on Saturday.
The agreement involves transfer of these two marketing divisions, along with employees to Strides for a consideration of Rs 165 crore, it said.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.